Coastline Trust Co Sells 1,123 Shares of Eli Lilly and Company $LLY

Key Points

• Coastline Trust Co. reduced its Eli Lilly stake by 5.4%, selling 1,123 shares and retaining 19,745 shares valued at approximately $22.8 million. Institutional investors and hedge funds collectively own 82.53% of the company.
• Analyst sentiment remains positive: Eli Lilly has a consensus “Moderate Buy” rating and an average price target of $1,311.96, despite some recent insider selling and one analyst’s “reduce” rating.
• Eli Lilly reported stronger-than-expected quarterly results, with EPS of $8.38 versus the $6.40 estimate and revenue up 47.7% year over year to $22.97 billion. Shares recently traded at $1,147.39, below the 52-week high of $1,292.65.

Coastline Trust Co decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 19,745 shares of the company's stock after selling 1,123 shares during the period. Eli Lilly and Company comprises 2.1% of Coastline Trust Co's portfolio, making the stock its 14th biggest position. Coastline Trust Co's holdings in Eli Lilly and Company were worth $22,847,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of LLY. Coastal Bridge Advisors LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $2,959,000. Mosaic Family Wealth Partners LLC boosted its position in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after purchasing an additional 1,430 shares during the period. Moran Wealth Management LLC raised its position in shares of Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock valued at $25,072,000 after purchasing an additional 9,638 shares during the period. Generali Investments Management Co LLC raised its position in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock valued at $12,258,000 after purchasing an additional 1,521 shares during the period. Finally, Amundi lifted its stake in shares of Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company's stock worth $4,649,464,000 after buying an additional 454,549 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an "overweight" rating in a report on Monday. Bank of America increased their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. HSBC lifted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a report on Thursday, September 10th. Finally, UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,311.96.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $9.69 during midday trading on Thursday, reaching $1,147.39. The company's stock had a trading volume of 825,816 shares, compared to its average volume of 2,985,028. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a market cap of $1.08 trillion, a P/E ratio of 38.46, a P/E/G ratio of 1.45 and a beta of 0.50. The business's 50 day moving average price is $1,178.06 and its two-hundred day moving average price is $1,087.21. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts forecast that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo delivered encouraging Phase 3 data. Lilly’s oral GLP-1 met its primary endpoint in the ATTAIN-1 study, while post-hoc analyses indicated a potential 57% reduction in predicted 10-year type 2 diabetes risk and an 18% reduction in predicted cardiovascular-disease risk versus placebo. The treatment also demonstrated cardiovascular safety, sustained A1C improvement and weight loss in the ACHIEVE-4 diabetes study. Lilly Foundayo risk-reduction results
• Positive Sentiment: Lilly’s next-generation obesity pipeline strengthened. The experimental EloraTZP combination produced substantially greater weight loss and A1C reduction than Zepbound alone in a Phase 2b trial, supporting plans to begin Phase 3 testing in the fourth quarter. Separate Phase 3 data showed retatrutide produced average weight loss of nearly 21% in adults with diabetes and obesity. EloraTZP trial results
• Positive Sentiment: Additional pipeline data broadened the growth story. Lilly reported positive results for EBGLYSS in hand and foot atopic dermatitis, including improved skin clearance, itching and pain. The company is also presenting obesity and diabetes data at the EASD meeting, reinforcing its competitive position in GLP-1 medicines. EBGLYSS trial results
• Neutral Sentiment: Competition remains intense. Novo Nordisk reported real-world evidence favoring higher-dose Ozempic over Mounjaro on observed cardiovascular risk, while other pharmaceutical companies are advancing competing oral and next-generation obesity treatments. The findings could increase uncertainty around Lilly’s long-term market share, even as its own clinical data remain strong. Novo cardiovascular comparison
• Negative Sentiment: The valuation leaves less room for disappointment. After a multiyear rally, investors are increasingly focused on whether future cash flows justify Lilly’s premium valuation. Concerns about potential U.S. price pressure and the stock’s recent decline may be contributing to profit-taking.
• Negative Sentiment: Lilly ended its cancer partnership with Foghorn Therapeutics. The collaboration was discontinued after disappointing early-stage results, and Foghorn plans significant layoffs. While the financial impact on Lilly appears limited, the decision highlights the risks in its broader development pipeline. Foghorn partnership termination

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.